Antibacterial

3-Oxo-C14-AHL (N-(3-Oxotetradecanoyl)-DL-homoserine lactone) 是由革兰氏阴性菌产生的群体感应 (QS) 信号分子，可用来提高能农作物的产量。

Rimonabant hydrochloride (SR 141716A) 是中心大麻素受体 1 的高效选择性反向激动剂， Ki 值为1.8 nM。它也能够抑制分枝杆菌膜蛋白3。

SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a multifunctional inhibitor of SARS CoV-2 3CLpro, exhibiting antiviral, antibacterial, and antifungal activities.

Oridonin (NSC-250682) 是从Rabdosia rubescens 中得到的二萜，是一种AKT 抑制剂，对 AKT1 和 AKT2 的IC50值分别为 8.4 和 8.9 μM，具有抗菌、抗炎、抗肿瘤等功效。

Chloroxine (Capitrol) 是重要的 8-羟基喹啉衍生物之一，有抗细菌，抗真菌，抗原生动物和抗阿米巴虫活性，可研究肠道阿米巴病，还可研究头皮屑和头皮脂溢性皮炎。

Carumonam, an antibiotic, could enhance the reactivity of Escherichia coli with mono- and polyclonal antisera to rough Escherichia coli J5.

Chlorhexidine (Rotersept) 是一种抗菌剂和防腐剂。它可用于注射前、手术前或外伤后清洁皮肤。

Pracinostat (SB939) 是一种组蛋白去乙酰化酶抑制剂，对 HDACs 的IC50值为 40-140 nM，可用于研究癌症。

Chlorobutanol hemihydrate (Chlorbutol hemihydrate) 是一种具有口服毒性的防腐剂，具有抗菌活性，抑制革兰氏阳性、革兰氏阴性细菌和真菌，可在体外抑制人血小板的聚集和释放，常用于化妆品中。

broad spectrum antibiotic

Ceftolozane sulfate (FR-264205) 是一种头孢菌素类抗生素，具有广谱的抗菌活性，抑制 P. aeruginosa PAO1,抑制假单胞菌，可用于研究肺炎。

β-Lactamase-IN-6 is a β-Lactamase inhibitor that shows high antibacetrial activity.

CRS3123 (REP-3123) dihydrochloride 是一种口服具有活力的全合成抗菌剂，能够有效抑制 Clostridioides difficile 甲硫氨酰-tRNA 合成酶 (MetRS)。CRS3123 dihydrochloride 能够用于 Clostridioides difficile 感染 (CDI) 的研究。

Somantadine 具有抗病毒活性，可用于预防和治疗冠状病毒相关疾病的研究。

LolCDE-IN-2 是一种有效的 Lol 蛋白(LolCDE)抑制剂。LolCDE-IN-2 具有抗菌活性，抑制大肠杆菌 MG1655 的 MIC 值为 2 μg/ml。

Nigericin sodium salt 属于抗生素，是一种 NLRP3 激活剂，也是一种阳离子离子载体。Nigericin sodium 可以触发 NALP3 炎性体的激活，可抑制高尔基体功能并抑制革兰氏阳性菌的生长。

LpxA-IN-1 是一种新型的 UDP-N-乙酰氨基葡萄糖酰基转移酶 (LpxA)抑制剂（IC502 nM）。LpxA-IN-1 具有抑制 Pseudomonas aeruginosa（MIC 8 μg/mL）的活性。

Psoralidin 是COX-2和5-LOX 的抑制剂，有抗癌，抗菌和抗炎作用。它显著下调NOTCH1信号传导，还极大地诱导活化氧产生。

2-(1H-Indol-3-yl)ethan-1-ol (3-(2-Hydroxyethyl)indole) 是在双硫仑治疗后在肝脏中形成的代谢物，可诱导人类睡眠。它也是酒精发酵的二次产物。

PXYC2 是一种核糖体蛋白 S1 (RpsA) 拮抗剂，对 RpsA-CTD 和 RpsA-CTD Δ438A 的 Kd 分别为 6.35 和 5.11 μM。在结核分枝杆菌 (Mtb)转译过程中，RpsA 发挥重要作用。

1,3-dihydroxy-4-methoxy-10-methylacridin-9-one 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN2491，CAS号为 1189362-86-4。

Ceftazidime Pentahydrate 是一种头孢类抗生素，对革兰氏阴性杆菌（包括铜绿假单胞菌）具有活性，可用于研究感染性疾病。

Cilastatin (MK0791) 是一种可逆的竞争性的肾脏脱氢肽酶 I 抑制剂，IC50为 0.1 μM。它抑制细菌金属叶内酰胺酶CphA 的IC50为 178 μM，可用作抗菌辅助剂。

Hibifolin 是一种黄酮醇糖苷，是潜在的腺苷脱氨酶抑制剂。它可以保护神经元免受 beta-淀粉样蛋白诱导的毒性。

G0507 is a pyrrolopyrimidinedione compound that serves as a potent inhibitor of Escherichia coli growth, effectively inducing the extracytoplasmic σE stress response. It acts as a valuable chemical probe, specifically designed to dissect lipoprotein trafficking in Gram-negative bacteria. Notably, G0507 demonstrates strong inhibitory activity against the LolCDE ABC Transporter.

Protein kinase G inhibitor-2 具有抗菌、抗病毒和抗肿瘤活性。

6'-Sialyllactose Sodium Salt (6'-N-Acetylneuraminyl-D-lactose sodium salt)是一种存在于母乳中的低聚糖，对 LPS 诱导的 ALI 具有保护作用，通过抑制 STAT1 和 NF-κB 信号通路来减轻 LPS 诱导的肺损伤。

Micronomicin (Gentamicin C2b) 是一种具有抗菌和杀菌能力的抗生素。

Ionomycin 是一种钙离子载体和一种结合钙离子(Ca2+)的抗生素。Ionomycin主要作用是通过增加细胞内钙离子浓度来诱导细胞反应。在实验中，Ionomycin通常用于激活钙依赖性过程，如细胞凋亡、酶活性等。

Antibacterial agent 131 是一种具有抗菌作用的化合物。

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg/ml) and Kurono (MIC: 0.0005 μg/ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg/ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg/ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg/ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg/kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1/2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg/kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg/kg to 2.5 mg/kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg/kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

FPI-1523, a derivative of Avibactam, is a potent inhibitor of β-lactamase enzymes. It has Kd values of 4 nM and 34 nM for CTX-M-15 and OXA-48, respectively. Additionally, FPI-1523 inhibits PBP2 with an IC50 of 3.2 μM and demonstrates significant antimicrobial activity.